# Simulect

NDC: 0078-0331
Generic name: basiliximab
Labeler / Manufacturer: Novartis Pharmaceuticals Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 19980512

FDA application: BLA103764

## Active ingredients

- BASILIXIMAB: 20 mg/5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0078-0331"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0078-0331
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1af01887-b69d-444b-91ed-ebfe12784440